Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by RetailRubeon Jul 31, 2012 9:51am
167 Views
Post# 20168437

HOLX takeover of GPRO

HOLX takeover of GPRO

Just a reminder that GPRO shareholder vote on acceptance of the HOLX takeover closes today.  Assuming the takeover goes through, the combined entity would be free to engage in corporate acquisitions such as buying out CUR's right to a royalty stream.  Or for simplicity, just buying CUR.  There are those of you who debate whether GPRO was going to bother with an offer until they saw the success of the PCA3 test in the marketplace.  But I think you will agree the HOLX pending takeover would have stalled any dealmaking by GPRO.  It would have made it too messy for the lawyers and investment bankers to have two offer circulars on the table simultaneously.

 

I also wonder what the wholesale price for the PCA3 test will be in the US if the retail price is $1200 instead of $300.  At $300, the wholesale price was $100 and CUR got a percentage of the $100.  That left $200 for the lab to keep them interested.  But at $1200, is it really necessary to have a $400 wholesale price (4x)?  Maybe it could be $600 and still leave enough for the lab to be interested.  This would help CUR.

 

<< Previous
Bullboard Posts
Next >>